Three cases of diabetic nephropathy successfully treated with camostat mesilate.
スポンサーリンク
概要
- 論文の詳細を見る
Although strict control of plasma glucose is necessary for the management of diabetic nephropathy, effective treatment for massive proteinuria has not yet been established. We examined the effect of a protease inhibitor, Camostat Mesilate, on diabetic patients with massive proteinuria. Camostat Mesilate (600 mg/day) was given orally to three diabetic patients in the nephrotic stage. Urinary protein was markedly decreased after the treatment for one or two weeks in all patients and stayed at a low level for several months.<BR>It has been suggested that the inhibitory effects of Camostat Mesilate on platelet aggregation, coagulation and free radical activity improve the renal function and decrease proteinuria, but the details remain unknown.<BR>We conclude that Camostat Mesilate is useful in reducing the urinary protein excretion in some, if not all, patients with diabetic nephropathy.
- 一般社団法人 日本糖尿病学会の論文
一般社団法人 日本糖尿病学会 | 論文
- Hyperlipidemia and Analysis of the Use of Lipid-lowering Drugs in Non-insulin-dependent Diabetes Mellitus.
- Thyrotoxic Crisis in a Patient with Mitochondrial Diabetes Mellitus.
- Rapidly Progressive Nephropathy in a Young Patient with Mitochondrial Gene Mutation.
- An Autopsy Case of Ketoacidosis in Insulin Dependent Diabetes Mellitus Patient Complicated with Adult Respiratory Distress Syndrome, DIC and Leukopenia.
- Studies on Alcoholic Beverages in Relation to Body Weight for Mild Diabetics